Bicara Therapeutics/$BCAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Ticker

$BCAX
Sector
Primary listing

Employees

55

BCAX Metrics

BasicAdvanced
$634M
-
-$2.35
-
-

Bulls say / Bears say

Bicara has begun dosing patients in its FORTIFI-HN01 pivotal Phase 2/3 trial evaluating ficerafusp alfa in combination with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma, marking a move into late-stage development.
Updated Phase 1/1b data presented at ASCO 2025 showed deep and durable responses with ficerafusp alfa plus pembrolizumab in HPV-negative recurrent/metastatic head and neck cancer, including a median duration of response of 21.7 months and median overall survival of 21.3 months.
With roughly $490 million in cash and cash equivalents as of December 31, 2024, Bicara possesses a strong balance sheet expected to fund operations through the first half of 2029, bolstering continued clinical progress.
Bicara’s pipeline is concentrated on a single lead asset, ficerafusp alfa, leaving the company vulnerable to binary clinical risk if this program does not succeed.
Even though dosing in the pivotal Phase 2/3 FORTIFI-HN01 trial started in February 2025, there is still no efficacy data available, creating considerable uncertainty for investors regarding trial outcomes.
In Q4 2024, Bicara posted a net loss of $20.96 million, highlighting a high cash burn that could strain the company’s cash runway if research and development costs keep climbing.
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCAX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs